Bob:

The one that I am co-riding to glory with MNKD is EXEL (Prostate, Skin, Breast and Bone Met Resolution).

Its already got one Indication for MTC (Met. Thyroid Cancer) approved with growing market share but this is a very small populus in the US (500 - 700) and has also been approved for Individual Case application by the Euro (EMA?) equivalent of FDA.

Wont go into it much further here as I have already set up an Agoracom board on the subject about 18 months ago, but it really hasn't had many takers thus far.

When I got into EXEL I was hoping that the buyout would have occured back in Dec 12 after intial FDA approval and possible comendium listing for off label application. I would have taken half of the House's money and plowed it into MNKD at the 2.50 range. You can imagine my disappointment at it suttering on the launch pad...

OOG